Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Register now for Commodity Ki Paathshala webinar on ‘FPOs & Agriculture Marketing-The Beginning of a New Era’ on January 22, 4pm
you are here: HomeNewsBusiness

Lupin gets USFDA nod for generic inhalation solution

The company has received tentative approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of Sunovion Pharmaceuticals Inc's Brovana inhalation solution, Lupin said in a statement.

April 29, 2020 / 03:22 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug maker Lupin on Wednesday said it has received approval from the US health regulator to sell Arformoterol Tartrate inhalation solution, used to treat chronic obstructive pulmonary disease.

The company has received tentative approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of Sunovion Pharmaceuticals Inc's Brovana inhalation solution, Lupin said in a statement.

The product is indicated for the long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

As per IQVIA's moving annual total till February 2020, Arformoterol Tartrate inhalation solution had an annual sales of around $489 million in the US.
PTI
first published: Apr 29, 2020 03:15 pm

stay updated

Get Daily News on your Browser
Sections